Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Top Stories > GENKYOTEX PROVIDES BUSINESS UPDATE FOR Q1 2017

GENKYOTEX PROVIDES BUSINESS UPDATE FOR Q1 2017

Published by Gbaf News

Posted on April 29, 2017

4 min read

Last updated: January 21, 2026

Lawmaker Kim Leadbeater discusses UK's assisted dying law changes - Global Banking & Finance Review — Image of Kim Leadbeater addressing the media about proposed changes to the UK's assisted dying law, emphasizing the removal of High Court judge sign-off to enhance the legislative process.

Cash & cash equivalents of €21.8 million as of March 31, 2017

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provided a corporate update and announced its cash & cash equivalents and liquid investments position for the first quarter ended March 31, 2017.

Business highlights

On February 28, 2017, the shareholders of Genticel approved the resolutions implementing the strategic combination between GenticelandGenKyoTex, pursuant to the contribution agreement signed on December 22, 2016 between Genticel and GenKyoTex’ shareholders, as well as the change of the Company’s name from “Genticel” to “Genkyotex” as from February 28, 2017. The shareholders also approved the appointments of:
- Claudio Nessi, Ilias (Elias) Papatheodorou, Eclosion 2 & Cie SCPC, Edmond de Rothschild Investment Partners, Catherine Moukheibir, and Mary Tanner as board members; and
- Stéphane Verdood and Joseph McCrackenas board observers.
On the same day, the board of directors of the Company appointed Claudio Nessi as Chairman of the Board, and Elias Papatheodorou asChief Executive Office of the combined Company.

Clinical highlights

The Company is on track with the preparation for the initiation of its Phase 2 trial with GKT831 in primary biliary cholangitis (PBC). The trial is expected to begin by the end of the first half of 2017.

In addition, Genkyotex is pursuing the development ofits second clinical candidate,GKT771, through ongoing IND enabling studies,and intends to initiate a Phase 1 clinical trial by the end of 2017, as planned.

Research highlights

Genkyotex also continues to explore the therapeutic value of NOX inhibition in oncology, hearing loss and Parkinson’s disease. The Company seeks opportunities of non-dilutive grant financing to support the preclinical evaluation of drug candidates in these areas.

Financial highlights

As of March 31, 2017, Genkyotex’s cash & cash equivalents was €21.8 million (vs. €26.7 million on December 31, 2016), in line with the Company’s expectations. The cash position does not include the expected reimbursement of Research Tax Credit (Crédit Impôt Recherche) for 2016,which the company has estimated to be at about€3.0 million.

Cash & cash equivalents of €21.8 million as of March 31, 2017

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provided a corporate update and announced its cash & cash equivalents and liquid investments position for the first quarter ended March 31, 2017.

Business highlights

On February 28, 2017, the shareholders of Genticel approved the resolutions implementing the strategic combination between GenticelandGenKyoTex, pursuant to the contribution agreement signed on December 22, 2016 between Genticel and GenKyoTex’ shareholders, as well as the change of the Company’s name from “Genticel” to “Genkyotex” as from February 28, 2017. The shareholders also approved the appointments of:
- Claudio Nessi, Ilias (Elias) Papatheodorou, Eclosion 2 & Cie SCPC, Edmond de Rothschild Investment Partners, Catherine Moukheibir, and Mary Tanner as board members; and
- Stéphane Verdood and Joseph McCrackenas board observers.
On the same day, the board of directors of the Company appointed Claudio Nessi as Chairman of the Board, and Elias Papatheodorou asChief Executive Office of the combined Company.

Clinical highlights

The Company is on track with the preparation for the initiation of its Phase 2 trial with GKT831 in primary biliary cholangitis (PBC). The trial is expected to begin by the end of the first half of 2017.

In addition, Genkyotex is pursuing the development ofits second clinical candidate,GKT771, through ongoing IND enabling studies,and intends to initiate a Phase 1 clinical trial by the end of 2017, as planned.

Research highlights

Genkyotex also continues to explore the therapeutic value of NOX inhibition in oncology, hearing loss and Parkinson’s disease. The Company seeks opportunities of non-dilutive grant financing to support the preclinical evaluation of drug candidates in these areas.

Financial highlights

As of March 31, 2017, Genkyotex’s cash & cash equivalents was €21.8 million (vs. €26.7 million on December 31, 2016), in line with the Company’s expectations. The cash position does not include the expected reimbursement of Research Tax Credit (Crédit Impôt Recherche) for 2016,which the company has estimated to be at about€3.0 million.